InsidersTradesSigma
Follow the 鹭燕医药 share price and the full directors' dealings record of the company, a listed issuer based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 鹭燕医药 has published 9 insider filings. Market capitalisation: €3.9bn. The latest transaction was filed on 28 November 2024 (Sale). Among the most active insiders: 雷鸣. Every trade is free.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€831,192
9 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,667 of 29,064 companies
47.8
score / 100
Value69
Quality26
FCF yld12%
Earn yld7.2%
EV/EBITDA12.6x
ROE8.3%
Gross mgn7.1%
Net mgn1.3%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 November 2024
Declarations9 total
9 of 9 declarations
关于 鹭燕医药
鹭燕医药是一家在医疗保健和制药领域运营的公司，在XSHE市场上市。该公司专注于药品的开发和分销。